Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Morris, Michael J.
O'Donoghue, Joseph A.
Chetty, Dushen
Russell, Mike
Zulch, Emma
Avadhani, Anjali Narayan
Divgi, Chaitanya R.
Pandit-Taskar, Neeta
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] J&J, Berwyn, PA USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Columbia Univ, Meadowbrook, Qld, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS249
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6
    Thuy Tran
    Timmermand, Oskar Vilhelmsson
    Axelsson, Susan Evans
    Pettersson, Kim
    Bjartell, Anders
    Lilja, Hans
    Ulmert, David
    Strand, Sven-Erik
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [2] A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer
    Pandit-Taskar, Neeta
    O'Donoghue, Joseph A.
    Chetty, Dushen
    Max, Steven
    Wanik, Danielle
    Ilovich, Ohad
    Russell, Michael
    Nyima, Tenzin
    Divgi, Chaitanya R.
    Yu, Margaret
    Morris, Michael J.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (07) : 1051 - 1056
  • [3] SPECT/CT imaging of the human kallikrein-2 (hK2) expression in prostate cancer using the humanized monoclonal antibody h11B6
    Tran, Thuy
    Elgqvist, Jorgen
    Strand, Sven-Erik
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [4] Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6
    Oskar Vilhelmsson Timmermand
    David Ulmert
    Susan Evans-Axelsson
    Kim Pettersson
    Anders Bjartell
    Hans Lilja
    Sven-Erik Strand
    Thuy A Tran
    EJNMMI Research, 4
  • [5] A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)
    Morris, Michael J.
    Wong, Jeffrey Y. C.
    Nordquist, Luke
    Szmulewitz, Russell Zelig
    Agarwal, Neeraj
    Attiyeh, Edward F.
    Max, Steven I.
    Divgi, Chaitanya R.
    Patricia, Daniel
    Cao, Yu
    Li, Xiang
    Yu, Alex
    Urtishak, Karen
    Lauring, Josh David
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    CANCER RESEARCH, 2012, 72
  • [7] Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6
    Timmermand, Oskar Vilhelmsson
    Ulmert, David
    Evans-Axelsson, Susan
    Pettersson, Kim
    Bjartell, Anders
    Lilja, Hans
    Strand, Sven-Erik
    Tran, Thuy A.
    EJNMMI RESEARCH, 2014, 4
  • [8] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [9] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
    McKay, Rana R.
    Werner, Lillian
    Jacobus, Susanna J.
    Jones, Xandra
    Mostaghel, Elahe A.
    Marck, Brett T.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Sweeney, Christopher J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2019, 125 (04) : 524 - 532
  • [10] CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer
    Smith, Matthew Raymond
    Piulats, Josep M.
    Todenhofer, Tilman
    Lee, Jae-Lyun
    Arija, Jose Angel Arranz
    Mazilu, Laura
    Azad, Arun
    Alonso-Gordoa, Teresa
    McGovern, Ursula Brigid
    Choudhury, Atish Dipankar
    Ye, Dingwei
    Suzuki, Hiroyoshi
    Mckay, Rana R.
    Ades, Steven
    Flechon, Aude
    Pieczonka, Christopher Michael
    Hulstijn, Maarten
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345